Lenvatinib plus Cisplatin refractory or unsuitable for ICI

Phase II study of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for the paitents with advanced hepatocellular carcinoma refractory or unsuitable for immune-checkpoint inhibitor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041210163

Enrollment

Registered

2022-03-17

Start date

2022-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma Hepatocellular carcinoma

Interventions

lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin

lenvatinib, cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; refractory or unsuitable for immune checkpoint inhibitor; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Design outcomes

Primary

Measure	Time frame
Objective response rate according to RECIST	—

Secondary

Measure	Time frame
progression-free survival, overall survival, objective response rate according to modified RECIST, tumor control rate, subsequent therapies, adverse events, liver functional reserve	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026